Pennsylvania Trust Co raised its stake in Edwards Lifesciences Corp. (NYSE:EW) by 25.0% during the third quarter, Holdings Channel reports. The firm owned 53,823 shares of the medical research company’s stock after buying an additional 10,760 shares during the period. Pennsylvania Trust Co’s holdings in Edwards Lifesciences Corp. were worth $6,489,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in EW. Arizona State Retirement System increased its position in shares of Edwards Lifesciences Corp. by 2.0% in the first quarter. Arizona State Retirement System now owns 61,800 shares of the medical research company’s stock valued at $5,451,000 after buying an additional 1,200 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Edwards Lifesciences Corp. by 48.5% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 25,693 shares of the medical research company’s stock valued at $2,268,000 after buying an additional 8,389 shares during the period. CenturyLink Investment Management Co acquired a new position in shares of Edwards Lifesciences Corp. during the second quarter valued at $207,000. British Columbia Investment Management Corp increased its position in shares of Edwards Lifesciences Corp. by 11.7% in the second quarter. British Columbia Investment Management Corp now owns 145,782 shares of the medical research company’s stock valued at $14,539,000 after buying an additional 15,291 shares during the period. Finally, Exxonmobil Investment Management Inc. TX increased its position in shares of Edwards Lifesciences Corp. by 4.9% in the second quarter. Exxonmobil Investment Management Inc. TX now owns 54,815 shares of the medical research company’s stock valued at $5,467,000 after buying an additional 2,566 shares during the period. Hedge funds and other institutional investors own 83.08% of the company’s stock.

Institutional Ownership by Quarter for Edwards Lifesciences Corp. (NYSE:EW)

Edwards Lifesciences Corp. (NYSE:EW) traded down 0.32% on Tuesday, reaching $84.03. The company’s stock had a trading volume of 1,873,641 shares. The stock has a market capitalization of $17.97 billion, a P/E ratio of 33.21 and a beta of 0.71. Edwards Lifesciences Corp. has a 52 week low of $72.20 and a 52 week high of $121.75. The firm has a 50 day moving average price of $99.49 and a 200 day moving average price of $106.55.

Edwards Lifesciences Corp. (NYSE:EW) last posted its quarterly earnings results on Tuesday, October 25th. The medical research company reported $0.68 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.68. Edwards Lifesciences Corp. had a net margin of 19.24% and a return on equity of 24.32%. The company earned $739.40 million during the quarter, compared to the consensus estimate of $749.14 million. During the same period last year, the firm earned $0.54 EPS. The company’s revenue for the quarter was up 20.1% on a year-over-year basis. On average, equities analysts anticipate that Edwards Lifesciences Corp. will post $2.88 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Pennsylvania Trust Co Purchases 10,760 Shares of Edwards Lifesciences Corp. (EW)” was first posted by Financial Market News and is owned by of Financial Market News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The correct version of this story can be accessed at http://www.financial-market-news.com/pennsylvania-trust-co-purchases-10760-shares-of-edwards-lifesciences-corp-ew/1208912/.

Several research analysts recently weighed in on EW shares. Zacks Investment Research downgraded Edwards Lifesciences Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Canaccord Genuity reaffirmed a “buy” rating and set a $140.00 price target on shares of Edwards Lifesciences Corp. in a research report on Thursday, August 18th. Evercore ISI reaffirmed a “hold” rating and set a $115.00 price target on shares of Edwards Lifesciences Corp. in a research report on Friday, August 19th. Credit Suisse Group AG set a $116.00 price target on Edwards Lifesciences Corp. and gave the stock a “buy” rating in a research report on Thursday, August 18th. Finally, Morgan Stanley reaffirmed a “buy” rating and set a $140.00 price target on shares of Edwards Lifesciences Corp. in a research report on Friday, August 19th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-two have assigned a buy rating to the stock. Edwards Lifesciences Corp. currently has an average rating of “Buy” and a consensus price target of $117.68.

In other news, CEO Michael A. Mussallem sold 49,100 shares of the firm’s stock in a transaction that occurred on Thursday, October 27th. The shares were sold at an average price of $92.77, for a total transaction of $4,555,007.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 18,000 shares of the firm’s stock in a transaction that occurred on Friday, September 2nd. The stock was sold at an average price of $115.78, for a total transaction of $2,084,040.00. The disclosure for this sale can be found here. Insiders own 2.37% of the company’s stock.

About Edwards Lifesciences Corp.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

5 Day Chart for NYSE:EW

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp. (NYSE:EW).

Receive News & Ratings for Edwards Lifesciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.